Investors excited about a new diagnostic platform have been pushing shares of Zomedica (NYSEMKT: ZOM) through the roof recently. The stock has already doubled in 2021, and a successful launch this spring could push it up even higher.

People sheltering in place during the COVID-19 pandemic adopted a lot of pets, accelerating a long-running trend toward increased spending on pet care services. Can Zomedica and its patented point-of-care tests for adrenal and thyroid diseases deliver big gains for investors?

Image source: Getty Images.

Continue reading

Source Fool.com